Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Director | June 16, 2026 | June 18, 2026 |
| Entasis Therapeutics Holdings Inc.ETTX · Entity 16036 | Director | July 07, 2022 | July 11, 2022 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | Director · Chief Executive Officer | January 20, 2023 | January 24, 2023 |
| uniQure N.V.QURE · Entity 4162 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.55 · Expires 2026-06-16 | Direct | 25,319 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 25,319 · Balance 25,319 F1: The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.
Entasis Therapeutics Holdings Inc.
Report date July 07, 2022 · Filed July 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-07 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2022-07-07 · Other · Disposed 22,000 · Balance 0 F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2022-07-11 · Disposition to issuer · Disposed 27,500 · Balance 0 F2: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-11 · Other · Disposed 17,307 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.98 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-11 · Other · Disposed 11,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price").
F2: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20.
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable.
Mirati Therapeutics, Inc.
Report date January 20, 2023 · Filed January 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,171 |
Reported balance
After 2023-01-20 transaction · row 1
1 source rowRow 1 · 2023-01-20 · Grant · Acquired 89,379 · Balance 151,171 F1: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20 | Direct | 151,233 |
Reported balance
After 2023-01-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-20 · Grant · Acquired 151,233 · Balance 151,233 F2: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.
F2: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
uniQure N.V.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 39,747 |
Ending reported balance
After 2026-06-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-10 · Grant · Acquired 7,550 · Balance 41,740 F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Row 2 · 2026-06-11 · Sale · Disposed 1,993 · Balance 39,747 F2: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.82 · Expires 2036-06-10 | Direct | 13,980 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Grant · Acquired 13,980 · Balance 13,980 F4: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
F2: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F4: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Fusion Pharmaceuticals Inc.
Report date June 04, 2024 · Filed June 04, 2024
Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-04 · Disposition to issuer · Disposed 34,000 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions.
F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 21:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 25,319 | $0.00 Strike: $13.55 | $0.00 |
DisclosureSEC source: 0001193125-26-276059 · ownership.xml · derivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,319 Underlying: Common Stock · 25,319 shares Expires 2026-06-16 F1 · derivative.exercise_date: The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 22:13 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 1,993 | $27.06 | $53,930.58 |
DisclosureSEC source: 0000904454-26-000352 · edgar.xml · nonDerivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,747 F2 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:13 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 13,980 | $0.00 Strike: $26.82 | $0.00 |
DisclosureSEC source: 0000904454-26-000352 · edgar.xml · derivative · entry 3 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,980 Underlying: Ordinary Shares · 13,980 shares Expires 2036-06-10 F4 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 22:13 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 7,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-26-000352 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,740 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 21:34 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,112 | $14.45 | $30,518.40 |
DisclosureSEC source: 0000904454-25-000328 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,190 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.40 to $14.50. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:09 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 38,513 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0000950170-25-086721 · ownership.xml · derivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,513 Underlying: Common Stock · 38,513 shares Expires 2035-06-12 F1 · derivative.exercise_date: The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:27 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 15,630 | $0.00 Strike: $16.22 | $0.00 |
DisclosureSEC source: 0000904454-25-000305 · edgar.xml · derivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,630 Underlying: Ordinary Shares · 15,630 shares Expires 2035-06-11 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:27 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 7,970 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-25-000305 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,302 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 21:10 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 15,840 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000904454-24-000403 · edgar.xml · derivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,840 Underlying: Ordinary Shares · 15,840 shares Expires 2034-06-19 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 21:10 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 8,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-24-000403 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,332 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 23:35 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,229 | $5.12 | $11,412.48 |
DisclosureSEC source: 0000904454-24-000373 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,252 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.12 to $5.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:25 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 34,000 | Not disclosed Strike: $4.16 | Not disclosed |
DisclosureSEC source: 0000950170-24-068892 · ownership.xml · derivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires not disclosed F1 · security: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| May 15, 2024 Filed May 16, 2024 21:40 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 15,618 | $0.00 Strike: $26.72 | $0.00 |
DisclosureSEC source: 0000950170-24-061228 · ownership.xml · derivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,618 Underlying: Common Stock · 15,618 shares Expires 2034-05-15 F1 · derivative.exercise_date: The option represents a right to purchase a total of 15,618 shares of the Issuer's common stock, which shall vest as to one-third of the shares underlying the option on each of the first, second and third anniversaries of the grant date of the award, subject to the Reporting Person's continued service as a director on each such vesting date. Read SEC document |
| October 16, 2023 Filed Oct 16, 2023 17:00 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001209191-23-052879 · doc4.xml · derivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2033-10-16 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 substantially equal monthly installments starting on November 16, 2023. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:25 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,290 | $18.85 | $43,166.50 |
DisclosureSEC source: 0000904454-23-000398 · edgar.xml · nonDerivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,481 F3 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F3 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.82 to $18.93. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 20, 2023 21:25 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 17,060 | $0.00 Strike: $20.18 | $0.00 |
DisclosureSEC source: 0000904454-23-000398 · edgar.xml · derivative · entry 3 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,060 Underlying: Ordinary Shares · 17,060 shares Expires 2033-06-13 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 13, 2023 Filed Jun 20, 2023 21:25 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-23-000398 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,771 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:09 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 389 | $19.71 | $7,667.19 |
DisclosureSEC source: 0000899243-23-006571 · doc4.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,071 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.71 to $19.99. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantEmployee Stock Option (Right to Buy) · Derivative | 151,233 | $0.00 Strike: $45.66 | $0.00 |
DisclosureSEC source: 0001214659-23-001042 · marketforms-58266.xml · derivative · entry 2 Meek David D. · CIK 0001555337 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,233 Underlying: Common Stock · 151,233 shares Expires 2033-01-20 F2 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 89,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-001042 · marketforms-58266.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,171 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 14:45 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 3,179 | $42.38 | $134,714.58 |
DisclosureSEC source: 0001214659-23-000810 · marketforms-58203.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,792 F1 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 14, 2022. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 02:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 4,616 | $40.41 | $186,551.95 |
DisclosureSEC source: 0001214659-22-015198 · marketforms-57925.xml · nonDerivative · entry 2 Meek David D. · CIK 0001555337 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,971 F3 · shares: Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the PSUs referenced in Footnote 1. Read SEC document |
| December 19, 2022 Filed Dec 22, 2022 02:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 35,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-015198 · marketforms-57925.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,587 F1 · kind: Award of Performance Stock Units ("PSUs"). 1/3 of the PSUs have vested on December 19, 2022 (one week after the "Achievement Date" of December 12, 2022). 1/3 of the remaining shares will vest on the one year anniversary of the Achievement Date and the remaining 1/3 will vest on the two year anniversary of the Achievement Date, subject to Mr. Meek's continuous service. F2 · balance_after: Includes 64 shares acquired under the ESPP Purchase on 5/31/2022 and 41 shares acquired under the ESPP purchase on 11/30/2022. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 20:07 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001104659-22-078797 · tm2220760-6_4seq1.xml · derivative · entry 4 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 20:07 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 17,307 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001104659-22-078797 · tm2220760-6_4seq1.xml · derivative · entry 3 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,307 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 20:07 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerCommon Stock | 27,500 | $2.20 | $60,500.00 |
DisclosureSEC source: 0001104659-22-078797 · tm2220760-6_4seq1.xml · nonDerivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. F2 · price: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:07 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherCommon Stock | 22,000 | $2.20 | $48,400.00 |
DisclosureSEC source: 0001104659-22-078797 · tm2220760-6_4seq1.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). F1 · price: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:22 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 17,810 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000904454-22-000352 · edgar.xml · derivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,810 Underlying: Ordinary Shares · 17,810 shares Expires 2032-06-15 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:22 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 9,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000352 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,460 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:34 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 602 | $16.70 | $10,053.40 |
DisclosureSEC source: 0000904454-22-000215 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,380 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.70 to $16.85. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 23:27 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 2,645 | $0.00 Strike: $16.04 | $0.00 |
DisclosureSEC source: 0000904454-22-000193 · edgar.xml · derivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,645 Underlying: Ordinary Shares · 2,645 shares Expires 2032-02-24 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 23:27 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 1,534 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000193 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,982 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 18, 2022 Filed Jan 19, 2022 21:01 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005415 · tm223320-4_4seq1.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,500 F1 · shares: This award vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service as a director of the Company. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 23:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantEmployee Stock Option (Right to Buy) · Derivative | 56,433 | $0.00 Strike: $124.31 | $0.00 |
DisclosureSEC source: 0001214659-22-000844 · marketforms-55093.xml · derivative · entry 2 Meek David D. · CIK 0001555337 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,433 Underlying: Common Stock · 56,433 shares Expires 2032-01-13 F2 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 23:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 34,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-000844 · marketforms-55093.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,057 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:11 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 150,300 | $0.00 Strike: $167.10 | $0.00 |
DisclosureSEC source: 0001214659-21-009784 · marketforms-53882.xml · derivative · entry 1 Meek David D. · CIK 0001555337 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,300 Underlying: Common Stock · 150,300 shares Expires 2031-09-21 F1 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:02 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 5,769 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001104659-22-023774 · tm226724-5_4seq1.xml · derivative · entry 4 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,769 Underlying: Common Stock · 5,769 shares Expires 2031-07-15 F5 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 7,500 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 5,769 shares of issuer's common stock, having an exercise price of $2.44 per share. F6 · derivative.exercise_date: The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:02 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $6.12 | Not disclosed |
DisclosureSEC source: 0001104659-22-023774 · tm226724-5_4seq1.xml · derivative · entry 3 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2029-06-18 F5 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 7,500 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 5,769 shares of issuer's common stock, having an exercise price of $2.44 per share. F4 · derivative.exercise_date: The option provided for vesting as follows: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:02 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 11,538 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001104659-22-023774 · tm226724-5_4seq1.xml · derivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2031-07-15 F2 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 11,538 shares of issuer's common stock, having an exercise price of $2.44 per share. F3 · derivative.exercise_date: The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:02 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $6.12 | Not disclosed |
DisclosureSEC source: 0001104659-22-023774 · tm226724-5_4seq1.xml · derivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-06-18 F2 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 11,538 shares of issuer's common stock, having an exercise price of $2.44 per share. F1 · derivative.exercise_date: The option provided for vesting as follows: The shares subject to this option will vest in equal monthly installments over the three years following the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 14:34 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-045913 · tm2111994-2_4seq1.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 18:58 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 505 | $37.50 | $18,937.50 |
DisclosureSEC source: 0000904454-21-000288 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,448 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.76 to $37.50. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:00 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 4,107 | $0.00 Strike: $37.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000254 · edgar.xml · derivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,107 Underlying: Ordinary Shares · 4,107 shares Expires 2031-02-25 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:00 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 2,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000254 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,953 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 10, 2020 Filed Oct 6, 2020 20:33 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001104659-20-112661 · a4.xml · derivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 20:54 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 3,620 | $0.00 Strike: $51.81 | $0.00 |
DisclosureSEC source: 0000904454-20-000263 · edgar.xml · derivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,620 Underlying: Ordinary Shares · 3,620 shares Expires 2030-02-27 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 20:54 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 2,063 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-20-000263 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,571 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| January 28, 2020 Filed Jan 31, 2020 01:54 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 718 | $62.20 | $44,659.60 |
DisclosureSEC source: 0000904454-20-000106 · edgar.xml · nonDerivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,508 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.20 to $62.21. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2020 Filed Jan 31, 2020 01:54 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 4 | $60.94 | $243.76 |
DisclosureSEC source: 0000904454-20-000106 · edgar.xml · nonDerivative · entry 1 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,226 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:04 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0001104659-19-037008 · a4.xml · derivative · entry 2 Meek David D. · CIK 0001555337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-18 F2 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments over the three years following the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.